A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of different doses of
M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting
toxicity (DLT) and the maximum tolerated dose (MTD) so as to provide basis for the
recommended phase 2 dose (RP2D).